Clinical Trial Update: Sho-Saiko-To Following Removal of Liver Cancer By Embolization in Treating Patients With Liver Cancer That Cannot Be Surgically Removed [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating Sho-Saiko-To for unresectable hepatocellular carcinoma treated with embolization has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Sho-Saiko-To

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Liver Cancer | Phase 2 | Status: COMPLETED